Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond progression.
The biopsy came back positive. It’s lung cancer.” Countless people in our community hear these words no one ever expects.
Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...
A previous study showed a confirmed objective response rate of 42.9% with the KRAS G12C inhibitor adagrasib in previously treated patients with NSCLC. In this phase III trial, median progression-free ...
February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and ...
A recent study has found that severe cases COVID-19 or influenza can leave lasting changes in the lungs that increase the risk of lung cancer years later. The study was conducted by researchers from ...
It can be surprising to learn that lung cancer can develop in people who have never smoked. In fact, up to 20% of lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results